Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin - Tolmar

Next Previous
Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; FENSOLVI; LA 2575; Leuprogel®; Leuprolide acetate - Tolmar; SOT-375; TOL-2506

Latest Information Update: 29 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator QLT USA
  • Developer MediGene AG; Recordati; Tolmar
  • Class Antineoplastics; Gonadotropins; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precocious puberty; Prostate cancer
  • Phase III HER2 negative breast cancer
  • Discontinued Endometriosis

Most Recent Events

  • 29 Jan 2026 Leuprorelin is still in phase III trial for HER2-negative-breast-cancer (Combination therapy) in USA, Argentina, Brazil, Canada, India, Mexico and Puerto Rico (SC)
  • 05 Jan 2026 Preregistration for Prostate cancer (Combination therapy, Late-stage disease) in United Kingdom (SC)
  • 05 Jan 2026 Preregistration for Prostate cancer (Late-stage disease) in United Kingdom (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top